AFP and hepatocellular carcinoma: Using 20 ng/mL for AFP, 40 mAU/mL for PIVKA-II, and 10% for AFP-L3% as the clinical cut-off values, the sensitivity of AFP, PIVKA-II, and AFP-L3% to detect HCC among patients with HCV-HCC were 59.5%, 76.8%, and 48.2%, respectively; the specificity was 89.6%, 87.1%, and 80.3%, respectively.